Abner Antonio Murray, Hematology/Oncology Fellow at UNC School of Medicine, shared a post by FlorezLab, adding:

“Incredible work by incoming Duaa Kanan at ASCO25. Her poster highlights a structure-based AI pipeline for identifying novel NSCLC therapies via FDA-approved and investigational drug repurposing.

Target: USP21, implicated in chemo resistance
Screened 687 molecules → 150 hits → 10 top leads via MD simulations
Translational potential in accelerating precision therapy for lung cancer

A proud showing from FlorezLab.”

Read OncoDaily’s Special Articles about ASCO 2025:

Highlights from ASCO 2025 Day 1

Highlights from ASCO 2025 Day 2

Highlights from ASCO 2025 Day 3

Highlights from ASCO 2025 Day 4

Abner Antonio Murray: Duaa Kanan’s Groundbreaking AI Pipeline for NSCLC Therapy at ASCO25

“Incredible work by incoming Duaa Kanan at ASCO25. Her poster highlights a structure-based AI pipeline for identifying novel NSCLC therapies via FDA-approved and investigational drug repurposing.

Target: USP21, implicated in chemo resistance
Screened 687 molecules → 150 hits → 10 top leads via MD simulations
Translational potential in accelerating precision therapy for lung cancer

A proud showing from FlorezLab.”

Read OncoDaily’s Special Articles about ASCO 2025:

Abner Antonio Murray: Duaa Kanan’s Groundbreaking AI Pipeline for NSCLC Therapy at ASCO25

“Incredible work by incoming Duaa Kanan at ASCO25. Her poster highlights a structure-based AI pipeline for identifying novel NSCLC therapies via FDA-approved and investigational drug repurposing.

Target: USP21, implicated in chemo resistance Screened 687 molecules → 150 hits → 10 top leads via MD simulations Translational potential in accelerating precision therapy for lung cancer

A proud showing from FlorezLab.”

Read OncoDaily’s Special Articles about ASCO 2025:

Target: USP21, implicated in chemo resistance
Screened 687 molecules → 150 hits → 10 top leads via MD simulations
Translational potential in accelerating precision therapy for lung cancer